TH1NG has recently entered into several new partnerships, received a breakthrough order, won a count...
Redeye retains its positive view of Sdiptech following a Q4 report that exceeded our expectations.
Redeye states the report was undramatic and broadly in line with our expectations.
Redeye comments on Alligator’s Q4 report. The key event during the quarter was mitazalimab showing s...
Better than most In a challenging macroeconomic environment Eastnine delivered one of the strongest ...
Russian divestment leaves ~SEK 800m net cash On 23 December 2022, Ferronrodic announced the divestme...
Redeye is encouraged to see continued solid performance in Q4.
Redeye lowers its near-term profitability outlook for QleanAir following its profit warning.
Last year was very good for Aspo despite the Russia exit, in our view.
Q4 sales of SEK 696m were 8% above ABGSCe With its strong order backlog and recent production data f...
Momentum looks solid Proact delivered an impressive Q4 report, growing sales 40% organically y-o-y, ...
Stark avslutning på 2022 med ökade hyresintäkter och en föreslagen utdelningshöjning på 13%.
Stark organisk tillväxt och stabil marginal Med flera samvarierande faktorer var marknaden fortsatt ...
Kraftigt påverkat av komponentbristen Det fjärde kvartalet påverkas kraftigt av den tidigare meddela...
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and s...
Redeye states that Catella posted another solid quarter despite rather challenging market conditions...
Redeye states that the Q4 report was largely in line with estimates.
Redeye updates its view on M.O.B.A. ahead of its Q4 2022 report due on February 15.
Ascelia’s leading SPARKLE study has recruited 71 (out of 80) patients, as announced earlier, and the...
IAR Systems’ Q4 report was a slight hiccup in its accelerated profitable growth turnaround, but we s...
